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Background: Non-small cell lung cancer (NSCLC) is the number one cancer killer. Tumor-initiating cells (TICs) are
responsible for tumor progression and recurrence. Emerging evidences suggest that small nucleolar RNAs (snoRNAs)
play malfunctioning roles in lung tumorigenesis. This study aims to determine if snoRNAs have important function
in lung TICs by: 1) profiling and comparing snoRNA expression patterns in lung ALDH1+/− cells of 28 primary
NSCLC tissues to identify new signatures of TICs; 2) determining prognostic significance of the snoRNA signatures
by analyzing the expression in 82 NSCLC tissues with different stages and histological types using quantitative PCR;
3) functionally investigating if the snoRNAs contribute to stemness of lung TICs using in vitro and in vivo assays.
Results: Twenty-two snoRNAs were identified whose changes were specific to the TICs. The expression of two
snoRNAs (snoRA3 and snoRA42) was inversely associated with survival of NSCLC patients (P = 0.002, p = 0.001,
respectively). Functional analysis indicated that snoRA42 was upregulated in CD133+ cells isolated from NSCLC cell
lines compared with the CD133- counterparts. snoRA42 knockdown reduced the proliferation and self-renewal of
TICs in vitro. However, ectopic expression of snoRA42 in non-TICs enhanced the potentials of cell proliferation and
self-renewal. snoRA42 expression was associated with expression of stem cell-core transcription factors in lung TICs.
Blocking snoRA42 expression in TIC xenografts decreased tumorigenesis in mice.
Conclusions: The snoRNA signatures of lung TICs provide potential biomarkers for predicting outcome of NSCLC.
snoRA42 is one of the important snoRNAs in regulating features of lung TICs, and thus contributes to lung
tumorigenesis.Background
Non-small cell lung cancer (NSCLC) is the leading
cause of cancer death for men and women worldwide.
With availability of more sensitive radiological imaging
studies, more NSCLC patients will be diagnosed while
the disease is still at early stage [1,2]. The standard of
care for NSCLC is surgery, often followed by chemo-
therapy [1]. However, approximately 84% of those diag-
nosed with lung cancer will die within five years [1].
Furthermore, the current chemotherapies often have
toxicity in normal host tissues, whereas tumor cells
rapidly develop resistance to anticancer agents. The
developments of biomarkers for identifying NSCLC
patients at high risk of recurrence after surgery, and* Correspondence: fjiang@som.umaryland.edu
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lung cancer are clinically important.
The existence of tumor-initiating cells (TICs), also
known as cancer stem cells, could explain why the
current chemotherapies cannot consistently eradicate
tumors, because the therapies only target the bulk of
tumor cells and are unable to eliminate TICs [3]. Fur-
thermore, residual lung TICs may regenerate a cancer
cell population, leading to tumor relapse after therapy.
TICs have been identified in lung cancer by using sev-
eral approaches such as CD133, a cell surface marker
[4]. We have recently characterized ALDH1+ cancer
cells are TICS, as the ALDH1+ cancer cells have exten-
sive self-renewal, proliferative, and in vivo tumorigenic
potentials [5-7]. The analysis of molecular aberrations
that characterize TICs would deep our understanding of
lung tumor biology. Furthermore, the molecular changesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mannoor et al. Molecular Cancer 2014, 13:104 Page 2 of 12
http://www.molecular-cancer.com/content/13/1/104could be developed as a new diagnostic system for mon-
itoring outcome of NSCLC. In addition, the TIC-related
molecular changes may enable the development of spe-
cific agents for eradicating the tumor-maintaining cells,
and thus provide efficient therapeutic approaches for
lung cancer.
Non-coding RNAs (ncRNAs) are functional transcripts
that do not code for proteins, however, play a crucial role
in regulating gene expression [8]. ncRNAs include small
nucleolar RNAs (snoRNAs), microRNAs (miRNAs), short
interfering RNAs (siRNAs), piwi-associated RNAs, small
Cajal body-specific RNAs (scaRNAs), snRNAs (small nu-
clear RNAs), and long ncRNAs [8]. Of the small ncRNAs,
miRNAs have extensively been studied in carcinogenesis
[9,10]. Dysregulation of some miRNAs is associated with
features of TICs. For example, elevated miR-181 clusters
were identified as vital regulators in hepatic TICs [11].
Furthermore, up-regulation of miR-199b-5p impaired
the development of TICs of medulloblastoma though
repression of HES1 [12]. In addition, the restoration of
miR-34 expression suppressed the self-renewal of pan-
creatic TICs [13].
Recently, new and unexpected functions of other types
of small ncRNAs have been discovered, revealing that
the molecules have highly diverse roles and are actively
involved in the processes of carcinogenesis than previously
thought [10]. In particular, several studies including our
own data suggest that snoRNAs exhibit differential ex-
pression patterns in lung tumor and have capability to
affect cell transformation, tumorigenesis, and metastasis
of NSCLC [10,14,15]. snoRNAs range between 60–150
nucleotides in length [16]. There are two classes of
snoRNAs: box C/D snoRNAs (snoRDs) and box H/ACA
snoRNAs (snoRAs) [16]. snoRDs serve as guides for the
2′-O-ribose methylation of rRNAs or snRNAs, whereas
snoRAs are guides for the isomerization of uridine resi-
dues into pseudouridine [17]. Accumulated evidence sug-
gests that snoRNAs can target other RNAs including
snRNAs and messenger RNAs [17]. For instance, HBII-52
regulates alternative splicing of 5-HT2CR by binding to a
silencing element in exon Vb [18,19]. Therefore, profiling
the expression patterns of snoRNAs in lung TICs may
help comprehend the functional repercussions of the
ncRNAs in the development and progression of NSCLC,
and hence provide diagnostic biomarkers and therapeutic
targets for the disease.
We propose to determine if aberrant snoRNAs have im-
portant function in lung TICs by: 1) profiling and compar-
ing snoRNA expression patterns in lung ALDH1+/− cells
of primary NSCLC tissues to identify signatures of TICs;
2) determining prognostic significance of the signatures by
analyzing the expression in NSCLC tissues; 3) functionally
investigating if the snoRNA signatures may contribute to
stemness of lung TICs.Results
Identifying snoRNA signatures of lung TICs
To identify snoRNA signatures of lung TICs, we first
used Aldefluor assay and fluorescence-activated cell
sorting to isolate ALDH1+ and ALDH1-cancer cells
from 28 primary NSCLC tumor tissues. The NSCLCs
comprised 15 adenocarcinoma (ACs) and 13 squamous
cell carcinomas (SCCs). Twenty-two of 28 NSCLC tis-
sues yielded ALDH1+ cells with an average of 2.2%
(±0.66), ranging from 0.7% to 3.2% of gated cells. We
then used the GeneChipR Array to analyze snoRNA
expression on the ALDH1 + cells and ALDH- cells of
the lung tumors. The GeneChipR Arrays contained
probes for 352 human mature snoRNAs. When P value
<0.01 was used as a cutoff, 22 snoRNAs displayed a
differential expression level with ≥ 3.0 fold-change in
ALDH1+ cancer cells compared with the correspond-
ing ALDH1- cancer cells (Figure 1 and Table 1). Of the
22 snoRNAs, 21 snoRNAs were overexpressed and one
snoRNA was underexpressed in ALDH1+ cancer cells
compared with the corresponding ALDH1- cancer
cells. The 22 snoRNAs provide new signatures of lung
TICs.Clinical significance of the lung TIC-snoRNA signatures
snoRA3 and snoRA43 displayed the highest expression
levels in TICs compared with non-TICs, and therefore
were chosen in the present study to be evaluated for
the clinical significance in 82 NSCLC tissues by quanti-
tative reverse transcriptase PCR (qRT-PCR) assay.
snoRA3 and snoRA43 had <35 threshold cycle (Ct)
value in all the tissue specimens. Univariate Cox re-
gression analysis showed that expression of the two
snoRNAs, age, and stage were significantly associated
with survival of the patients (All P < 0.05) (Additional
file 1: Table S2). However, there was no statistical
significant correlations between either race, or sex,
or tumor histological type, or smoking history and
survival of the patients (All P > 0.05). Furthermore, the
Kaplan-Meier Curve analysis suggested that the NSCLC
patients with a high expression level of the snoRNAs
had a poor survival compared with the patients who
had a lower level of the snoRNAs in the tumor tissues
(P = 002 and P = 001, respectively) (Figure 2). In addition,
multivariate Cox proportional-hazards model analyses
indicated that the two snoRNAs were statistically signi-
ficant after adjusting patient age and tumor stage,
suggesting their independent prognostic value from the
clinicopathologic features (P = 0.003 and P = 0.002,
respectively) (Additional file 1: Table S1). Therefore, the
assessment of the two TIC-snoRNA signatures might
provide a potential approach for predicting outcome of
NSCLC.
Table 1 Up-regulated and down-regulated snoRNAs in
TICs vs. non-TICs























TICs, tumor-initiating cells; non-TICs, non-tumor-initiating cells.
TICs were ALDH1 cells purified by Aldefluor assay.
Figure 1 1snoRNAs differentially expressed in TICs (ALDH1+ cells) versus non-TICs (ALDH1- cells) isolated from 22 non-small cell lung
cancer (NSCLC) tumor tissues. Hierarchical clustering of 22 snoRNAs with a significantly different expression (p < 0.01) in ALDH1+ cells versus
ALDH1- cells isolated from surgical NSCLC tumor tissues. Rows represent individual genes; columns represent individual samples.
Figure 2 Expression of snoRA3 and snoRA42 in lung tumor
tissues is inversely associated with survival of non-small cell
lung cancer (NSCLC) patients. (A) Probability of overall survival by
levels of snoRA3 expression in NSCLC. (B) Probability of overall
survival by levels of snoRA42 expression in NSCLC.
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TICs
snoRA42 is highly expressed in CD133+ cells isolated from
NSCLC cell lines
We used snoRA42 as an example to investigate whether
the TIC-snoRNA signatures could have important func-
tion in TICs. Because the snoRNA signatures were de-
fined from ALDH1+ cancer cells and CD133 is another
important marker for lung TICs, we used CD133+ and
CD133- cells that were isolated from a panel of NSCLC
cell lines to confirm if snoRA42 was specifically dys-
regulated in TICs. As shown in Figure 3A, snoRA42
expression increased by at least 2.5-fold in CD133+
cancer cells compared with the CD133- counterparts,
supporting that the snoRNA signature was enriched in
lung TICs.Downregulation of snoRA42 inhibits proliferation and
self-renewal of lung TICs
We explored whether snoRA42 downregulation could
inhibit cell growth and proliferation of lung TICs by
transfecting CD133+ cells isolated from NSCLC cell
lines with snoRA42-siRNA. snoRA42-siRNA produced
more than 75% reduction of snoRA42 expression in the
CD133+ cells compared with mock-transfected CD133+
cells or CD133+ cells transfected with the scrambled siRNA
(Figure 3B). The results suggested that the snoRA42-siRNA
could block snoRA42 expression in TICs. Furthermore,
there was a significant decrease of numbers of CD133+
cancer cells transfected with snoRA42-siRNA compared
with those with scrambled siRNA or mock transfection
(Figure 3C). The inhibition of snoRA42 silencing on cell
growth of TICs was confirmed by methylthiazol tetrazo-
lium (MTT) assay. The findings suggest that snoRA42
knockdown could have a significant inhibition on growth
and proliferation of lung TICs. In addition, CD133+ cancer
cells transfected with snoRA42-siRNA gave rise to sig-
nificantly fewer mammospheres (Figure 3D) compared
with CD133 + cancer cells treated with controls, implying
the downregulation of snoRA42 decreased the capacity
of mammosphere formation of TICs. Therefore, re-
duced snoRA42 expression in TICs could inhibit the
self-renewing capacity of lung TICs.Downregulation of snoRA42 reduces in vitro tumorigenesis
of CD133+ cells isolated from NSCLC cell lines
CD133+ cancer cells have been reported to exhibit highly
tumorigenic potential in terms of migration and invasion
[4,20,21]. We therefore investigated whether snoRA42
could play a role in tumorigenesis of CD133+ cells isolated
from NSCLC cell lines. As shown in Figure 4A, the spaces
between the two edges of wound scratches were more
spacious in siRNA-snoRA42- treated CD133+ cancercells compared with scrambled siRNA- or mock-treated
CD133+ cancer cells. Knockdown of snoRA42 inhib-
ited the adhesion properties of CD133+ cancer cells, as
manifested by lower density of cells 24 h post treat-
ment than cell density before wound assay was started.
Furthermore, there were significantly lower numbers
of siRNA-snoRA42-treated CD133+ cells migrating
across matrigel membrane compared with CD133+
cells treated with scrambled siRNA or mock transfec-
tion (Figure 4B). The findings suggested that snoRA42
knockdown could reduce migratory and invasive capabil-
ities of lung TICs. In addition, we investigated whether
siRNA-mediated suppression of snoRA42 could influence
anchorage-independent long-term differentiation capacity
of CD133+ cells by using soft agar colony formation assay.
After four weeks, siRNA-snoRA42 resulted in a significant
reduction of colony formation in terms of size and
number of CD133+ cancer cells compared to CD133+
cancer cells treated with controls (Figure 4C). The
results implied that snoRA42 suppression could reduce
the in vitro tumorigenesis of CD133+ cells isolated from
NSCLC cell lines.
snoRA42 knockdown induces caspase 3-dependent
apoptosis
To investigate possible mechanism underlying the inhib-
ition of in vitro tumorigenicity of TICs, we first evaluated
whether there was apoptosis in CD133+ cancer cells
treated with snoRA42-siRNA. As shown in Figure 4D, per-
centages of apoptotic cells were significantly increased
upon snoRA42 knockdown compared with scrambled
siRNA- and mock-treated CD133+ cancer cells. To con-
firm the finding, we applied enzyme-linked immunosorb-
ent assay (ELISA) to analyze cell lysate for determining
change of caspase-3. As shown in Figure 4E, cleaved cas-
pase-3 was activated prominently in CD133+ cells treated
with snoRA42-siRNA. Therefore, snoRA42 knockdown
could trigger apoptosis in CD133+ cells isolated from
NSCLC cell lines. The inhibition of cell proliferation and
self-renewal of lung TICs by snoRA42 suppression may be
achieved at least partially through inducing apoptosis.
Upregulation of snoRA42 increases in vitro tumorigenicity
of TICs
To further determine the role of snoRA42 on stemness
properties of TICs, we forced expression of snoRA42 in
non-TICs by transducing CD133-cells with a vector of
pCMV expressing snoRA42 (pCMV-snoRA42). As shown
in Figure 5, CD133-cancer cells with pCMV-snoRA42
displayed a higher expression level of snoRA42 com-
pared with CD133-cancer cells treated with pCMV
control (Figure 5A). As a result, CD133-cancer cells
with pCMV-snoRA42 formed bigger spheres in terms
of number (Figure 5B) and size compared with CD133-
Figure 3 (See legend on next page.)
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Figure 4 Downregulation of snoRA42 reduces in vitro tumorigenesis of CD133+ cells isolated from NSCLC cells. (A) snoRA42 knockdown
inhibited migration rate of H-1944- and Calu-1-derived CD133+ cells. A wound scratch assay was used to compare the migration rate of cells
treated with mock transfection, scrambled siRNA, or siRNA-snoRA42. The cells treated with siRNA-snoRA42 had a significantly higher level of migration rate
compared with the cells treated with mock transfection or scrambled siRNA. (B) downregulation of snoRA42 moderated matrigel barrier invasion of
H-1944- and Calu-1-derived CD133+ cells. Matrigel barrier invasion capability was compared among three different groups of CD133+ cells treated with
mock, scrambled siRNA, or snoRA42-siRNA. (C) snoRA42 knockdown significantly inhibited colony formation capability of H-1944- and Calu-1-derived
CD133+ cells. (D) snoRA42 knockdown induced apoptosis. Apoptosis of H-1944-derived CD133+ cells treated with scrambled siRNA and snoRA42-siRNA
was compared by staining the cells with Annexin V/PI (propidium iodide) followed by flowcytometric analysis. The numbers indicate percentages of
non-stained cells (Annexin V − PI−), early apoptotic cells (Annexin V + PI−) and late apoptotic or necrotic cells (Annexin V + PI+). (E). snoRA42A knockdown
caused activation of caspase 3 in H-1944- and Calu-1-derived CD133+ cells. ELISA assay was used to determine cleaved caspase 3 protein in CD133+
cancer cells treated with mock transfection, scrambled siRNA, or siRNA-snoRA42. CD133+ cells showed a higher level of caspase 3 activation compared
with CD133- cells after snoRA42 knockdown. *P values <0.05. The number of cells used in each experiment can be found in Methods.
(See figure on previous page.)
Figure 3 siRNA-mediated snoRA42 suppression inhibits proliferation and self-renewal of CD133+ cells isolated from NSCLC cell lines.
(A) There was a high level of expression of snoRA42 in CD133+ cells versus CD133- cells of a panel of NSCLC cells determined by qPCR analysis.
(B) siRNA-snoRA42 efficiently reduced snoRA42 expression in CD133+ cells isolated from NSCLC cell lines. qPCR analysis was performed to determine
snoRA42 expression in CD133+ cells treated with mock transfection, scrambled siRNA, or siRNA-snoRA42. (C) downregulation of snoRA42 decreased
cell growth of CD133+ cells isolated from NSCLC cell lines. The time-kinetics of cell proliferation rate of CD133+ cancer cell with mock transfection,
scrambled siRNA transfection, or siRNA-snoRA42 transfection was determined. Cell proliferation rate after snoRA42 knockdown in CD133+ cancer cells
was significantly reduced after 24 hours. (D) snoRA42 knockdown reduced the percentage of mammospheres of CD133+ cells. The experiments were
performed in all the NSCLC cell lines listed in Methods and had similar results. The number of cells used in each experiment can be found in Methods.
The figure only shows results from H-1944- and Calu-1-derived CD133+ cells. *P values <0.05.
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Figure 5 Upregulation of snoRA42 in CD133- cells isolated from NSCLC cell lines increases the in vitro tumorigenicity. (A) H-1944- and
Calu-1-derived CD133- cells transduced with pCMV-snoRA42 displayed an elevated level of snoRA42 expression. (B) Effect of snoRA42
overexpression on sphere formation of H-1944- and Calu-1-derived CD133- cells. H-1944- and Calu-1-derived CD133- cells transduced with
pCMV-snoRA42 had a higher growth rate of spheres compared with CD133- cells transduced with vector. (C) Effect of enforced expression of snoRA42
in H-1944- and Calu-1-derived CD133- cells on colony formation in soft agar. pCMV-control transduced and pCMV-snoRA42-transduced CD133- cells
were allowed to differentiate for four weeks in soft agar, respectively. Forced expression of snoRA42 significantly increased colony formation
capability of CD133- cells. (D) Ectopic expression of snoRA42 improved migration of H-1944-derived CD133- cells. A wound scratch assay was
used to measure migration rate of cells transduced with pCMV-control and pCMV-snoRA42 24 h post treatment. Forced snoRA42 expression in
CD133- cells caused a significant increase in migration capability of CD133- cells. *P values <0.05. The number of cells used in each experiment
can be found in Methods.
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number of the pCMV-snoRA42-transducted CD133-
cancer cells considerably increased compared with that
of CD133-cancer cells with pCMV control. In addition,
there were significantly greater numbers of colonies of
CD133-cancer cells with pCMV-snoRA42 compared to
CD133-cancer cells with pCMV control (Figure 5C).
Moreover, wound healing and matrigel transmigration
assays showed that migration rate of CD133-cancer
cells with pCMV-snoRA42 was higher compared with
CD133-cancer cells with pCMV control (Figure 5D).
Altogether, the gain-of-function experiments indicate that
upregulation of snoRA42 would enhance the in vivotumorigenicity of CD133- cancer cells isolated from
NSCLC cells.
snoRA42 knockdown inhibits in vivo tumorigenesis of
CD133+ cells isolated from NSCLC cell lines
To examine whether snoRA42 knockdown was associ-
ated with repression of in vivo tumorigenicity, we sub-
cutaneously inoculated CD133+ Calu-1 NSCLC cells
treated with either snoRA42-siRNA or scrambled siRNA
into the flanks of mice (5 × 105 cells/mouse). As shown
in Figure 6, tumor appeared in 100% mice that received
CD133+ Calu-1 NSCLC cells with scrambled siRNA
control. In contrast, CD133+ Calu-1 NSCLC cells with
Figure 6 Effect of snoRA42 suppression on tumor formation of CD133+ cells isolated from NSCLC cell lines and expressions of stem
cell-associated genes. (A) After six weeks, 5 X 105 Calu-1-derived CD133+ cells transfected with scrambled siRNA were able to generate tumor
xenografts (red arrow) in all six mice. However, 5 X 105 Calu-1-derived CD133+ cells transfected with snoRA42-siRNA could not produce tumor in
any mice. (B) Knockdown of snoRA42 using snoRA42-siRNA in H-1944- and Calu-1-derived CD133+ cells resulted in a significant reduction in
transcriptional activity of stem-associated genes determined by qRT-PCR.
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in any of the mice injected. These results are consistent
with those created from the above in vitro studies, and
further support that snoRA42 is associated with tumori-
genicity of lung TICs.
Dysregulation of snoRA42 is associated with expressions of
stem cell-associated genes
To determine if snoRA42 suppression could affect
expression of core stem cell transcription factors in
CD133+ cells isolated from a panel of NSCLC cell lines,
we quantified expression levels of stem cell-associated
genes by qRT-PCR. siRNA-mediated knockdown of
snoRA42 in CD133+ cells led to a significant decrease
in transcript levels of the genes, including Oct4, Nanog,
Sox2, Notch1, Smo, and ABCG2 compared to scrambled
siRNA-treated CD133+ cancer cells (Figure 6). Further-
more, to examine if enforced expression of snoRA42 could
have an opposite effects to that of snoRA42 knockdown,
we transduced CD133- cancer cells with pCMV-snoRA42.
Although the expression levels of different stem cell-
associated genes in snoRA42-transduced CD133- cancer
cells could not reach to that in CD133+ cancer cells, tran-
scriptional level of the stem cell-associated genes inCD133- cancer cells with pCMV-snoRA42 significantly
increased compared to CD133- cancer cells with empty
vector. Altogether, snoRA42 is associated with expression
of the stem cell-core transcription factors in lung TICs.
Discussion
Cancer arises from a tumorigenic subpopulation of TICs.
The identification of molecular signatures of lung TICs
provide a key standpoint for better understanding
tumorigenesis and developing prognostic biomarkers
and targeted therapy [22]. For instance, methylation of
TIC-associated Wnt target genes were identified in
colorectal tumors and showed the potential for pre-
dicting a poor prognosis of colon cancer patients [23].
Yet few molecular signatures of TICs in lung cancer
have been identified. By conducting transcriptomic
profiling ALDH1+/−NSCLC cells of primary tumor tis-
sues, here we successfully identify 22 novel snoRNA
signatures of lung TICs.
Although only two (snoRA3 and snoRNA42) of 22
snoRNAs are evaluated in the present study, the results in-
dicate that the aberrant expression of the TIC-snoRNAs is
associated with aggressive biological behavior of NSCLC.
Importantly, expression of the snoRNAs was inversely
Table 2 Demographic and clinical characteristics of 82
NSCLC patients
Characteristics No. of patients (%)


















NSCLC, non-samll cell lung cancer.
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the assessment of the TIC-snoRNA signatures might
provide a potential approach for predicting outcome of
NSCLC. However, as lung tumor is a heterogeneous dis-
ease, the analysis of the two TIC-snoRNA signatures can-
not achieve the accuracy required to move forward for a
clinical trial. Multiple biomarkers may provide more
accuracy in prediction of outcome of lung cancer. From
the identified 22 snoRNA signatures of lung TICs, we are
optimizing a panel of biomarkers that can more precisely
predict recurrence of NSCLC in our ongoing study.
snoRNAs have long been believed to modify and
stabilize rRNAs for ribosome production. Several recent
studies including our own observations demonstrate that
dysregulation of snoRNAs is a common molecular event
in carcinogenesis [14,15]. We previously found that
snoRA42 activation promoted lung cancer development
and progression [14]. The critic role of snoRA42 in
TICs is first supported by that expression of snoRA42 is
significantly elevated in CD133+ lung cancer cells com-
pared with CD133- lung cancer cells. Furthermore,
CD133- lung cancer cells with forced snoRA42 expression
have the capacity to enhance the in vitro tumorigenicity,
whereas the CD133- cells without forced snoRA42
expression do not. In addition, siRNA-mediated deple-
tion of snoRA42 causes reduction of expression of stem
cell-related genes, suppression of xenograft tumor forma-
tion, and inhibition of cellular proliferation and self-renewal
of TICs in vitro. The inhibition of cell proliferation and
self-renewal of lung TICs by snoRA42 dysregulation may
be attained through inducing caspase 3-dependent
apoptosis. Moreover, forced expression of snoRA42 in
CD133- lung cancer cells produces higher cell prolifera-
tion and expression levels of stem cell-associated genes
compared with CD133- lung cancer cells transduced
with empty vector. Therefore, the present study extends
the previous discoveries by finding that snoRA42 plays
an important role in regulating stemness of lung TICs,
and hence contributes to invasiveness and metastasis of
NSCLC. Targeting snoRA42 in future may serve as an
effective and specific therapeutic approach for lung can-
cer treatment. Nevertheless, investigating how the stem
cell-core factors are regulated by snoRA42, and if other
snoRNA signatures are also responsible to stemness fea-
tures of TICs is warranted. In fact, we are functionally
characterizing snoRA3 by using in vitro and in vivo
approaches to determine if snoRA3 has a significant
role in regulating stemness of lung TICs.
Conclusions
We identified novel snoRNA signatures of lung TICs. Two
of the signatures were evaluated in a cohort of NSCLC
specimens. The results showed that the overexpression
of the snoRNAs was inversely associated with survival ofNSCLC patients. In vitro and in vivo functional analyses
highlighted the importance of snoRA42 for the features
of lung TICs. The snoRNA signatures of lung TICs may
provide potential biomarkers for predicting outcome of
NSCLC and novel therapeutic targets.
Methods
Patients and clinical specimens
To prepare single primary tumor cells, we obtained 28 lung
tumor tissue specimens of NSCLC patents who underwent
surgical resection in the University of Maryland Medical
Center under appropriate institutional review board
approval. All cases were diagnosed with histologically
confirmed stage I NSCLC, comprising 15 patients with
AC and 13 patients with SCC. Furthermore, to validate
expression of snoRNAs in tumor tissue specimens, 82
frozen NSCLC tumor tissues were obtained. Clinical
characteristics and histopathological data of the speci-
mens are shown in Table 2. None of the patients had
received preoperative adjuvant chemotherapy or radio-
therapy before they received treatments.
Tissue process and cell culture
The surgical tumor specimens were processed for prepar-
ing single dissociated cells as previously described [4].
Briefly, the surgical specimens were washed three times
and left 12 hours in DMEM-F12 medium supplemented
with penicillin/streptomycin and amphotericin B. Tissue
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with collagenase II (Gibco-Invitrogen, Carlsbad, CA) for
two hours at 37°C. The dissociated cells were processed
for flow cytometric isolation of TICs based on ALDH
enzymatic activity as described below.
All NSCLC cell lines including A549, H299, H1792,
H226, H522, H-1944, Calu-1, and H460 were purchased
from the ATCC (Manassas, VA, USA). The cell lines
were maintained as monolayer cultures in high glucose
Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 50 μg/mL
normocin (Invivogen, San Diego, CA) at 37°C in a humidi-
fied incubator with 5%.
Flow cytometry isolation of ALDH1+ and ALDH1- cells
We isolated ALDH1 + cells from single dissociated cells of
lung tumors using an Aldefluor assay kit (Aldagen Inc.,
Durham, NC) as described in our previous reports [5-7].
1 × 106 cells per well were suspended in Aldefluor assay
buffer containing ALDH substrate, BAAA (1 μmol/L).
Cells stained with 50 mmol/L of the specific ALDH inhi-
bitor diethylaminobenzaldehyde (DEAB) were used as a
negative control. Flow cytometric sorting was carried out
using a FACSAria (Becton Dickinson, Mountain View,
CA). Aldefluor fluorescence was excited at 488 nm, and
fluorescence emission was detected using a fluorescein
isothiocyanate (FITC) 530/30-nm band-pass filter by a
FACS calibre machine (BD Biosciences, San Jose, CA).
Flow cytometry isolation of CD133+ and CD133- cells
from NSCLC cell lines
CD133+ and CD133- cells were isolated from NSCLC
cell lines as previously described [4]. Briefly, cells were
derived after trypsinization of adherent NSCLC cells.
Cells were washed twice with magnetic automated cell
sorting (MACS) buffer (Miltenyi Biotec Inc., San Diego,
CA). Cell pellets were then resuspended in 300 μl of
MACS buffer followed by addition of 100 μl of FcR
blocking reagent (Miltenyi Biotec Inc.), 100 μl CD133 of
microbeads (Miltenyi Biotec Inc.), and 50 μl of CD133/
2-PE antibody (Miltenyi Biotec Inc.). The cells were
washed with MACS buffer and MACS-assisted purifica-
tion was performed according to manufacturer’s instruc-
tions. Purity of CD133+ cells and CD133- cells were
checked by flowcytometry.
TIC-conditioned suspension culture for sphere production
For sphere-forming cultures, cells were plated at a dens-
ity of 2 × 104 cells per well in six-well ultra-low attach-
ment plates (Corning Inc., Corning, NY) in serum free
Bronchial Epithelial Cell Basal Medium (BEBM), supple-
mented with the following growth supplements: BPE,
Hydrocortisone, hEGF, Epinephrine, Transferrin, Insulin,
Retinoic Acid, Triiodothyronine, and GA-1000, providedas BEGM prepackaged SingleQuots (Lonza, Walkersville,
MD) plus rhEGF (Sigma, St Louis, MO), bFGF (Sigma).
Fresh aliquots of EGF and bFGF were added every three
days. Floating spheres were subjected to mechanical dis-
sociation, followed by replating of single cells for propa-
gation into a second, and subsequently into a third
batch of suspension culture as described in our previous
reports [5-7].
RNA isolation
We used a mirVana miRNA Isolation Kit (Ambion,
Austin, TX) to isolate RNA containing small RNA from
cells and tissue specimens as described in our previous
studies [24,25,15].
snoRNA profiling of lung TICs
snoRNA profiling was performed by using GeneChipR
Array (Affymetrix, Inc, Santa Clara, CA) as described in
our previous report [15]. Microarray experiments were
done with matched ALDH1+ and ALDH1- cells. One μg
total RNA was labeled with Biotin FlashTag Biotin
Labeling Kit (Affymetrix, Inc). The labeling reaction was
hybridized on the arrays in Affymetrix Hybridization Oven
640 (Affymetrix, Inc) for 16 hours. The arrays were stained
with Fluidics Station 450 using fluidics script FS450_0003
(Affymetrix, Inc), and then scanned on a microarray scan-
ner (Axon Instruments Inc, Foster City, CA). snoRNA
probe outliers were defined as per the manufacturer’s
instructions (Affymetrix, Inc) and further analyzed for
data summarization, normalization, and quality control
by using the web-based QC Tool software (www.affy-
metrix.com). The normalized microarray data under-
went further analysis as described in our previous study
[15]. We performed tree visualization by using Java
Treeview 1.0 (Stanford University School of Medicine,
Stanford, CA).
Quantification of snoRNA expression by qRT-PCR
Expressions of snoRNAs were determined by using real-
time SYBR green RT-qPCR assay as described in our
previous studies [14,15]. All PCR reactions were run on
a CFX96 Real-Time qPCR detection system (Bio-Rad,
Hercules, CA) using Brilliant SYBR green qPCR master
mix (Agilent Technologies, Chelmsford, MA). U6 was
used as an internal control gene. ΔCt was calculated by
subtracting the Ct values of U6 from those of the
snoRNA tested, and fold-change of each snoRNA was
determined by the equation 2–ΔΔCt. qRT-PCR was
also performed to decide expression levels of stem
cell-associated genes, which included ACTBF, ABCB1,
ABCG2, CD133, Nanog, Nestin, Notch, Oct4, Smo, and
Sox2. The primer sequences are included in Additional
file 1: Table S3.
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RNA interference assays were performed as described in
our previous study [14]. Briefly, specific target site of
designed siRNA in RNA sequence of snoRA42 (NCBI
accession number NR_002974) was a 19 nucleotide
stretch as follows: 5′-GTACCCATGCCATAGCAAA-3′.
Corresponding non-targeting scrambled sequence was
also designed. Transfection was performed by using
Opti-MEM and Lipofectamine™ RNAiMAX Reagent
(Invitrogen, CA, USA) as described elsewhere [26].
snoRA42 overexpression vector construction and
transduction with the vector
pCMV (pSilencer CMV 4.1; Ambion, Carlsbad, CA)-
snoRA42 vector was constructed for ectopic snoRA42
expression as described previously [14]. A vector com-
prising sequence that showed no significant homology to
the human genome databases was used as a control.
Transduction of cells with the vectors was performed as
described in our previous study [14].
Methylthiazol tetrazolium (MTT), 5-bromo-2'-deoxyuridine
(BrdU) incorporation, colony formation, transmigration,
and wound healing assays
MTT and BrdU incorporation assays were performed
as previously described [24,14]. Cells were seeded in
96-well plates at 1 × 104 cells per well. Colony forma-
tion was determined by using 3D soft gar matrix with a
0.8% of soft agar (noble agar) base layer followed by 0.4%
top agar layer containing cells at a density of 1 × 104 with
different treatments in 24-well culture plates. Colonies
were counted using inverted light microscopy. For trans-
migration assay, the ability of migration and invasion of
cells was examined using BD BioCoat Matrigel Invasion
Chambers (BD Biosciences) according to manufacturer’s
instruction. After 24 h, the migrated cells were pelleted
and counted using a hematocytometer. To further confirm
cell migration, a wound healing assay was performed in 12
well plates (1 × 105 per well). When the cells were grown
to 90 to 95% confluences, tranfection of CD133+ cells
with siRNA-snoRA42 and scrambled siRNA, as well as
mock transfection were performed. Wound lines were cre-
ated manually by scratching the monolayer with a sterile
200 ml pipette tip and migration of the cells was assessed
after 24 hours. Pictures were taken using Nikon inverted
phase-contrast microscope (Nikon, Melville, NY). The
distance between the parallel lines was measured using
ImageJ software. All experiments were carried out at
least three times.
Apoptosis assay
Cell apoptosis was determined by two-color immuno-
fluorescence staining followed by flowcytometric analysis.
Cells were trypsinized without EDTA (Sigma) followed bytwo washing steps with phosphate buffered saline. 2 ×
105 cells per well were then incubated with 5 μl of
FITC Annexin V (BD Pharmingen) and 5 μl of propi-
dium iodide (BD Pharmingen) in 400 μl of 1 × binding
buffer for 15 min at room temperature. Data acquisition
and analysis were performed on a FACScan flowcytometer
(Becton-Dickinson) using BD analysis software as de-
scribed previously [14].
Cleaved caspase ELISA
Cleaved caspase 3 ELISA was performed by using PathScan
Sandwich ELISA kit (Cell signaling Technology, Inc.,
MA) according to manufacturer’s instructions. Cyto-
chrome c-treated jurkat cell lysate was used as cleave
caspase 3 positive control, whereas untreated jurkat cell
lysate was used as cleaved caspase 3 negative control
(Cell signaling Technology, Inc.). Cleaved caspase index
was calculated as follows: (sample O.D. - negative control
O.D./positive control O.D.-negative control O.D.)/100.
Tumorigenicity assays in vivo
The animal study protocol was performed in accordance
with the guidelines of University of Maryland School of
Medicine Institutional Animal Care and Use Committee.
Six 6-week old female SCID/Beige mice per group were
subcutaneously inoculated with 5 × 105 Calu-1-derived
CD133+ cells with different treatments. The mice were
observed for six weeks and then euthanized with CO2.
Tumor volume was calculated by using the formula:
width × width × length × 0.52 [5-7,14].
Statistical analysis
Both univariate and multivariate Cox proportional hazard
models were applied to assess the effect of various clinically
and histopathologically interesting variants, and snoRNA
expression on overall survival data of patients. Association
of expression of the snoRNAs with overall survival rate was
also analyzed using the Kaplan-Meier method. All P-values
were determined by two-sided tests.
Additional file
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